Skip to main content

Published locations for Nemolizumab continues to crush itch in 64-week atopic dermatitis study

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Nemolizumab continues to crush itch in 64-week atopic dermatitis study

User login

  • Reset your password
  • /content/nemolizumab-continues-crush-itch-64-week-atopic-dermatitis-study
  • /edermatologynews/article/151356/atopic-dermatitis/nemolizumab-continues-crush-itch-64-week-atopic
  • /familypracticenews/article/151356/atopic-dermatitis/nemolizumab-continues-crush-itch-64-week-atopic
  • /dermatology/article/151356/atopic-dermatitis/nemolizumab-continues-crush-itch-64-week-atopic
  • /familymedicine/article/151356/atopic-dermatitis/nemolizumab-continues-crush-itch-64-week-atopic